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AbstrACt
Objectives Cancer survival and stage of disease at 
diagnosis and treatment vary widely across Europe. These 
differences may be partly due to variations in access 
to investigations and specialists. However, evidence to 
explain how different national health systems influence 
primary care practitioners’ (PCPs’) referral decisions 
is lacking. This study analyses health system factors 
potentially influencing PCPs’ referral decision-making 
when consulting with patients who may have cancer, and 
how these vary between European countries.
Design Based on a content-validity consensus, a list of 
45 items relating to a PCP’s decisions to refer patients 
with potential cancer symptoms for further investigation 
was reduced to 20 items. An online questionnaire with 
the 20 items was answered by PCPs on a five-point Likert 
scale, indicating how much each item affected their own 
decision-making in patients that could have cancer. An 
exploratory factor analysis identified the factors underlying 
PCPs’ referral decision-making.
setting A primary care study; 25 participating centres in 
20 European countries.
Participants 1830 PCPs completed the survey. The 
median response rate for participating centres was 
20.7%.
Outcome measures The factors derived from items 
related to PCPs’ referral decision-making. Mean factor 
scores were produced for each country, allowing 
comparisons.
results Factor analysis identified five underlying factors: 
PCPs’ ability to refer; degree of direct patient access 
to secondary care; PCPs’ perceptions of being under 
pressure; expectations of PCPs’ role; and extent to which 
PCPs believe that quality comes before cost in their health 
systems. These accounted for 47.4% of the observed 
variance between individual responses.
Conclusions Five healthcare system factors influencing 
PCPs’ referral decision-making in 20 European countries 
were identified. The factors varied considerably between 
European countries. Knowledge of these factors could 
assist development of health service policies to produce 
better cancer outcomes, and inform future research 
to compare national cancer diagnostic pathways and 
outcomes.
bACkgrOunD 
There is wide variation in cancer survival 
rates across Europe.1 Data from the fifth 
cycle of the European Cancer Registry-based 
Study on Survival and Care of Cancer 
Patients (EUROCARE-5) show that the 1-year 
relative survival rate for all cancer sites varies 
from 58.2% to 81.1% between countries1 
strengths and limitations of this study
 ► The questionnaire was developed using content va-
lidity reduction and factor analysis of a consensus 
item pool, and therefore grounded in primary care 
practitioners' (PCPs’) clinical experience.
 ► PCPs were recruited from 20 European countries, 
4  countries from each of the Central, Eastern, 
Northern, Southern and Western European geo-
graphical areas.
 ► Most samples were taken from each local lead’s 
own locality, and these may not have been repre-
sentative of their nations as a whole.
 ► The response rate was low but comparable to that 
of other equivalent surveys of primary care doctors.
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(table 1). Although 1-year relative survival can be affected 
by differences in registration (eg, completeness and use 
of death certificates), and lead-time and overdiagnosis 
biases,2 3 it is generally taken to be an indicator of more 
advanced disease at diagnosis.4 5 Survival differences in 
the subsequent 4-year period (known as ‘5|1-year condi-
tional survival’) are narrower, suggesting that earlier diag-
nosis could reduce the 1-year relative survival gap.6 This 
is supported by increasing evidence that longer time to 
diagnosis and treatment may adversely affect mortality.7–13 
While recent overall cancer survival trends show improve-
ments,14 there is little narrowing in the between-country 
survival differences.15 
The challenge of where and how to achieve more timely 
diagnosis is considerable.16 A general practitioner (GP) 
will see only a small number of new cancers each year, 
for example, a GP in the United Kingdom (UK) will on 
average have a new cancer diagnosed in one of his or her 
patients each month.17 The majority of cancers are iden-
tified because the patient has been experiencing symp-
toms. However, most patients present with evolving and 
undifferentiated symptoms that are much more likely to 
be interpreted as something other than cancer.16
GP gatekeeping, in which patients’ access to specialists, 
hospital care and diagnostic tests needs to be authorised 
by GPs,18 is the cornerstone of many European medical 
Table 1 EUROCARE-5 1-year relative and 5|1-year conditional cancer survival rates for European countries,1 with ranks given
Country
1-year relative 
survival (%)
1-year relative 
survival: rank
5|1-year conditional 
survival (%)
5|1-year conditional 
survival: rank
Austria 75.9 11 60.1 7
Belgium 78.9 3 60.4 6
Bulgaria 58.2 28 38.7 28
Croatia 62.1 25 46.2 22
Czech Republic 68.3 19 50.7 19
Denmark 69.8 18 50.9 18
Estonia 65.9 22 46.0 24
Finland 76.9 8 61.4 4
France 77.8 7 58.6 10
Germany 76.7 9 59.1 9
Greece (not available) (not available)
Iceland 78.3 6 61.2 5
Ireland 70.3 16 54.0 15
Israel (Arabs)* 78.6 4 61.4 3
Israel (Jews)* 82.8 1 68.9 1
Italy 74.9 12 56.8 12
Latvia 60.9 27 41.7 26
Lithuania 63.8 24 46.1 23
Malta 70.0 17 52.9 16
Netherlands 73.0 14 54.6 14
Norway 76.1 10 58.6 11
Poland 61.7 26 40.6 27
Portugal 74.0 13 56.4 13
Romania (not available) (not available)
Slovakia 65.4 23 44.8 25
Slovenia 67.7 21 47.8 21
Spain 71.5 15 52.8 17
Sweden 81.1 2 64.8 2
Switzerland 78.3 5 59.2 8
UK 67.9 20 50.1 20
European mean 72.5 54.2
*Calculated from data provided by B Silverman, Israel Ministry of Health (personal communication, 7 September 2017).
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systems.19 There is evidence that stronger gatekeeper 
systems are linked with lower 1-year relative cancer survival 
than systems without such gatekeeper functions.20 This 
may be because gatekeeping systems can impose cost and 
resource decisions which impede early referral for investi-
gation.21 However, there are wide variations in the degree 
of gatekeeping between countries, with no simple binary 
model as to whether or not a country has a ‘GP-as-gate-
keeper’ system, and a European study found no link 
between a higher probability of initial consultation with 
a GP and poorer cancer survival.22
The way in which different healthcare systems support 
primary care in cancer diagnosis by quick and easy access 
to investigations may also be a factor in timeliness of 
cancer diagnosis.23 It has been suggested that GPs need 
faster routes to diagnostic tests and/or specialist opinion 
for all patients with a suspicious symptom, above a certain 
threshold.21 In the UK, use of an urgent cancer referral 
pathway has been found to be associated with reduced 
mortality24 and a reduction in the proportion of cancers 
diagnosed through emergency presentations.25 An Inter-
national Cancer Benchmarking Partnership (ICBP) study 
demonstrated a correlation between the readiness of 
primary care practitioners (PCPs) to investigate suspi-
cious symptoms and cancer survival rates.26 No consistent 
associations were found between how likely practitioners 
were to investigate and PCP demographics, practice or 
health system variables. However, there was no explo-
ration of how individual doctors felt that health system 
factors affected their decision-making.
The Örenäs Research Group is a European group of 
primary care researchers that studies the primary care 
factors that relate to cancer survival. It has identified a 
large variety of non-clinical factors that are likely to have a 
considerable impact on PCPs’ referral decision-making.27 
These include levels of gatekeeping responsibility, 
funding systems, access to investigations and relation-
ships with specialist colleagues. However, there has been 
little research done to explain how these vary between 
countries.16
This study investigated the health system factors poten-
tially influencing European PCPs’ decision-making with 
regard to investigating patients who may have cancer, and 
how these vary between European countries.
MethODs AnD Design
Design
We performed an international online survey of PCPs 
in 20 European countries between November 2015 and 
December 2016. Some of the methodology described 
here reproduces information already reported in our 
published protocol paper.28
Development of the questionnaire
Following a literature review, 7 Örenäs Research Group 
investigators developed and agreed by consensus a list of 
45 items, each relating to predefined aspects/concepts 
that may affect a PCP’s decision to refer patients with 
potential cancer symptoms for further investigation. A 
questionnaire based on these items was piloted by 16 
members of the Örenäs Research Group to assess content 
validity. Six of the items were removed due to low content 
validity. An English-language questionnaire with the 
remaining 39 items was piloted by 49 PCPs in 16 Örenäs 
Research Group member countries (table 2). Nineteen 
items were found to show little or no variation between 
countries and were removed from the questionnaire, 
leaving 20 items.
Örenäs Research Group leads arranged for translations 
of the questionnaire into their local languages where 
these were not English, a total of 19 translations from 
the original English. Translation and validation were 
done in a standardised way29: native speakers of the local 
languages who were fluent in English and were medi-
cally qualified did the ‘forward’ translations. ‘Backward’ 
translations into English were then made by translators 
who were fluent in both English and their local language. 
The forward translations were then compared with the 
backward ones, to assess semantic and conceptual equiva-
lence.30 Discrepancies between the forward and backward 
translations were resolved by discussion with the trans-
lators, following which the final translation was agreed 
on. Finally, in each country the corrected versions were 
piloted in a small sample of PCPs to evaluate the instruc-
tions, response format and the items for clarity and to 
ensure cultural adaptation.30
the questionnaire and distribution
The final questionnaire sought demographic informa-
tion (table 3) and presented the 20 health system factor 
items (listed in table 4). Respondents were asked to rate 
how much they agreed with each item in relation to their 
referral decision-making for patients who could have 
cancer. A five-point Likert rating scale was provided for 
participants, with response options ranging from ‘strongly 
disagree’ to ‘strongly agree’. The questionnaires were put 
online using SurveyMonkey. Online methodology was 
used to aid the logistics of survey administration; online 
surveys have been successfully used in research involving 
cancer care professionals.31
study population
The study was conducted in 25 Örenäs Research Group 
centres in 20 countries across Europe: Bulgaria, Croatia, 
Denmark, England, Finland, France, Germany, Greece, 
Israel, Italy, Netherlands, Norway, Poland, Portugal, 
Romania, Scotland, Slovenia, Spain, Sweden and Swit-
zerland. Local study leads were asked to either gain 
ethical approval or obtain a statement that formal ethical 
approval was not needed in their jurisdiction (see online 
supplementary file).
Subjects were eligible for the survey if they were doctors 
working mainly in primary care. These doctors, here 
referred to collectively as ‘PCPs’, included GPs and other 
doctors who had had specialist training but worked in the 
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Table 2 Results of questionnaire pilot
Response
Number of 
countries in 
which piloting 
PCPs agreed 
with statement
Number of 
countries in 
which piloting 
PCPs were 
unsure
Number of 
countries in 
which piloting 
PCPs disagreed 
with statement
Even if there are no ‘red-flag’ symptoms, we usually refer if we have a 
feeling that something is wrong.*
11 4 0
Here, high-quality care for an individual patient is always more important 
than costs.
5 6 5
If we have ‘over-referred’, our own income may be reduced.* 1 3 12
If we organise any investigations, we pay for that themselves.* 1 2 13
In some practices, patients often have to travel a long way to see a 
specialist.
9 5 2
Long waiting lists for specialists or tests mean that we sometimes delay a 
referral/special investigation until it is really necessary.*
1 10 5
Many primary care doctors have special investigations (eg, diagnostic 
ultrasound) in their practices.*
1 5 10
Missing a diagnosis of cancer is something that we particularly worry 
about.*
15 0 0
Patients can self-refer to specialists, so we do not need to act as a 
gatekeeper.
5 1 10
Patients sometimes criticise us if they think we delayed a cancer 
diagnosis because of a late referral.*
13 3 0
Paying for a specialist can be a problem for some of our patients. 5 4 7
Referral costs are usually paid by insurance companies, not primary care 
or hospital budgets.
6 3 7
Referring or not referring does not affect our income at all. 10 3 3
Some of our referral systems (eg, online referral systems) make the 
referral process more difficult.*
1 4 11
Specialists often try to reduce referrals to them.* 1 5 10
Specialists often welcome referrals. 6 7 3
Specialists sometimes criticise us if they think that a cancer diagnosis 
was slow because of a late referral.*
12 3 1
Specialists sometimes criticise us if they think that we should have been 
able to look after the patient ourselves.
7 5 4
There is a special, quick specialist appointment system for patients with 
suspected cancer.
8 3 5
Usually, patients prefer a general practitioner (rather than a specialist) to 
look after them.
6 6 4
We are asked not to refer patients with a low risk of cancer.* 1 4 11
We are asked to refer any patients with possible cancer early, even if 
there is a low risk of cancer.
6 7 3
We are likely to refer if the patient is very worried that he/she has cancer, 
even if there are no ‘red flag’ symptoms.*
12 2 1
We are likely to refer if the patient says that she/he would like to be 
referred, even if there are no red flags.
8 3 4
We are often worried about the risk of unnecessary (and possibly harmful) 
investigations.*
12 2 1
We are under media (newspaper, television) or public pressure to refer 
earlier.
5 4 6
We are under media (newspaper, television) or public pressure to refer 
less.*
1 3 11
Continued
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community and could be accessed directly by patients 
without referral.
sample size
A total sample size of 1000 or more responses was calcu-
lated to be sufficient to obtain stable factor estimates 
within the exploratory factor analysis,32 based on each 
jurisdiction recruiting at least 50 respondents. This 
provided a 95% CI of at most ±14%.
recruitment of participants
Each Örenäs Research Group local lead was asked 
to email an invitation to take part in the survey to the 
PCPs in their local health district, and to recruit at least 
50 participants. In six countries (Denmark, Norway, 
Portugal, Romania, Slovenia, Sweden), the invitation 
was distributed to a national sample. Any local leads who 
had difficulty in achieving the required sample sizes were 
asked to increase the number of responses by using snow-
balling.33 Consent was implied by agreeing to take part in 
the survey. All data were collected anonymously.
statistical analysis
The demographic characteristics of the respondents 
were explored using descriptive statistics. Likert scale 
responses were converted to numerical scores (‘strongly 
disagree’=1, ‘strongly agree’=5). An exploratory factor 
analysis was undertaken on these responses, to identify 
underlying factors and to test the predefined constructs.
We used a principal components method,34 with a 
direct oblimin rotation to allow for correlated factors. 
The number of components was defined by inspection of 
the scree plot and the Kaiser criterion (eigenvalue ≥1). 
Between-country variation in these factors was then 
examined and presented as means with 95% CIs. We 
made a sensitivity analysis with weighting of the responses 
to adjust for the differing numbers of respondents per 
country. Calculations were performed using IBM SPSS 
V.22.
Patient and public involvement
There was no patient or public involvement in this study.
results
A total of 1830 PCPs completed the questionnaire. All 
participating centres received at least 50 responses, with a 
median of 72 respondents per centre. PCPs’ demographic 
distributions are shown in table 3. The median response 
rate per country was 20.8% (range 6.7%–57.8%).
The mean national Likert-scale values for each of the 
20 questions are given in table 4.
The factor loadings for each of the 20 items are shown 
in table 5. The factor analysis identified five factors 
which accounted for 47.4% of the variance of individual 
responses. The factor means for each participating 
country and their 95% CIs are given in table 6.
Response
Number of 
countries in 
which piloting 
PCPs agreed 
with statement
Number of 
countries in 
which piloting 
PCPs were 
unsure
Number of 
countries in 
which piloting 
PCPs disagreed 
with statement
We are usually very busy, so we sometimes refer to help reduce our 
workload.
6 5 5
We can easily email a specialist for advice. 5 3 8
We can easily telephone a specialist for advice. 5 5 6
We can refer directly to a named specialist. 8 4 4
We have a budget for patient care costs, but we share it with secondary 
care.*
0 2 14
We have a budget or quota (maximum limit) for referrals.* 1 3 12
We have a budget or quota (maximum limit) for special tests. 4 2 9
We have guidelines that help us decide which patients to refer. 7 2 7
We often refer to a specialist that we know personally. 8 6 2
We usually have enough time in the consultation to think carefully about 
whether the patient needs a referral.
6 6 4
We worry about the possibility of legal action or a formal complaint if we 
refer late.*
8 7 1
Writing a good referral letter takes time, and as we are usually very busy 
we sometimes delay making a referral.*
1 2 13
*These statements were removed from the final questionnaire because either (a) one or no piloting countries agreed with the statement, or (b) 
one or no piloting countries disagreed with the statement.
Table 2 Continued 
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Factor 1: primary care practitioners’ ability to refer
This factor contained six items. A higher score on this 
factor indicated lower barriers to specialist referral, more 
time during the consultation to consider whether the 
patient needs a referral and absence of criticism from 
colleagues over referrals that were perceived to be unnec-
essary. This factor explained 15.5% of the variance of 
individual responses. A comparison of national scores for 
factor 1 is shown in figure 1.
Factor 2: degree of direct patient access to secondary care
This factor contained six items. A higher score for this 
factor was linked with items relating to direct patient 
access to secondary care: the absence of a GP gatekeeping 
role, with higher financial and geographical barriers to 
healthcare for some patients, and in some cases the pres-
ence of a quota for diagnostic tests. Higher scores for 
this factor were also linked with less likelihood of having 
a fast-track specialist appointment system for patients 
with suspected cancer. Factor 2 explained 10.8% of the 
variance of individual responses, and the comparison of 
national scores for this factor is shown in figure 2.
Factor 3: primary care practitioners’ perceptions of being 
under pressure
This factor contained four items. A higher score was linked 
with perceptions of pressure on the PCP from a high 
workload, as well as demands from patients, the public 
and the health system. It explained 7.6% of the variance 
of individual responses. A comparison of national scores 
for factor 3 is shown in figure 3.
Factor 4: expectations of the primary care practitioners’ role
This factor contained two items. A higher score for this 
factor was associated with higher expectations of PCP-cen-
tred care, and the presence of guidelines to support PCP 
decision-making. It explained 6.7% of the variance of 
individual responses, and a comparison of national scores 
for this factor is shown in figure 4.
Factor 5: quality before cost
This factor contained two items. A higher score was 
linked with PCP perceptions that in their systems high 
quality care for patients was more important than costs, 
and that financial aspects had less effect on their referral 
Table 3 Number of respondents per country and 
demographic distributions.
Country
Number of respondents (% 
of all respondents)
  Bulgaria 51 (2.8)
  Croatia 56 (3.1)
  Denmark 92 (5.0)
  England 62 (3.4)
  Finland 61 (3.3)
  France 52 (2.8)
  Germany 91 (5.0)
  Greece 59 (3.2)
  Israel 58 (3.2)
  Italy 60 (3.3)
  Netherlands 107 (5.8)
  Norway 81 (4.4)
  Poland 135 (7.4)
  Portugal 59 (3.2)
  Romania 146 (8.0)
  Scotland 62 (3.4)
  Slovenia 91 (5.0)
  Spain 379 (20.7)
  Sweden 68 (3.7)
  Switzerland 60 (3.3)
  Total 1830 (100)
Respondent gender 
  Female 1108 (60.5)
  Male 708 (38.7)
  Not stated 14 (0.8)
  Total 1830 (100)
Years since graduation 
  <10 284 (15.5)
  10–19 492 (26.9)
  20–29 535 (29.2)
  30–39 442 (24.2)
  40 or over 69 (3.8)
  Not stated 8 (0.4)
  Total 1830 (100)
Site of practice 
  Urban 1086 (59.6)
  Rural 426 (23.3)
  Island 50 (2.7)
  Mixed 268 (14.6)
  Total 1830 (100)
Number of doctors in practice 
  1 252 (13.8)
  2 210 (11.5)
Continued
Country
Number of respondents (% 
of all respondents)
  3 196 (10.7)
  4–5 304 (16.6)
  6–7 235 (12.8)
  8–9 153 (8.4)
  10 or more 470 (25.7)
  Not stated 10 (0.5)
  Total 1830 (100)
Table 3 Continued 
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decision-making. This factor explained 6.4% of the vari-
ance of individual responses. A comparison of national 
scores for factor 5 is shown in figure 5.
sensitivity analysis
In a sensitivity analysis with weighting of the responses 
to adjust for the differing numbers of respondents per 
country, only one statement moved to a different factor: 
the statement "In my practice, patients often have to 
travel a long way to see a specialist" moved from factor 
2 to factor 4.
DisCussiOn
Principal findings
Based on a content validity process, a 45-item pool on 
referral decision-making for patients who could have 
cancer was reduced to a 20-item questionnaire. From the 
responses of 1830 PCPs, from 25 primary care centres 
in 20 European countries, 5 key factors were identified: 
PCPs’ ability to refer; degree of direct patient access to 
secondary care; PCP perceptions of being under pressure; 
expectations of the PCPs’ role; and the extent to which 
PCPs believe that, in their systems, quality comes before 
cost. The factors showed significant variation between the 
participant countries.
interpretation of the results
Based on the content validity and the significant variation 
between countries, the survey can be regarded as relevant 
for studying aspects of PCPs’ perceptions of what affects 
their referral and investigation of patients with symptoms 
that could be due to cancer. Thus, the developed ques-
tionnaire could be used in further research to evaluate 
associations with cancer outcomes, and could also be 
used to evaluate changes in healthcare systems regarding 
referring patients who could have cancer.
Factor 1. PCPs’ ability to refer: the variation in PCPs’ 
ability to refer was linked to structural differences like 
barriers to specialist referrals (including waiting times), 
the degree of criticism of PCPs relating to their referrals, 
the quality of relationships between PCPs and specialists 
and the length of the PCPs’ consultations with patients. 
This was the most important factor, carrying most of the 
explained variation, and consequently it appears to be 
particularly important in explaining between-country 
differences in primary care cancer diagnosis.
Factor 2. Degree of direct patient access to secondary 
care: this important factor was related to the extent to 
which GPs were gatekeepers and to which public systems 
provided universal access to healthcare, whether self-re-
ferral to specialists was possible outside the public health 
system, patients’ ability to travel to and fund specialist 
consultations and whether fast-track referral systems were 
in place for patients with suspected cancer.
Factor 3. PCPs’ perceptions of being under pressure: 
variations in PCPs' perceptions of being under pressure 
were linked with PCP workloads, patient expectations 
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and their level of trust in their doctors and the extent to 
which health systems expected PCPs to refer patients.
Factor 4. Expectations of the PCPs’ role: differing 
expectations of the PCPs’ role were related to whether 
there had been a shift of work and responsibility between 
secondary and primary care, and the extent to which 
patient care was from specialists rather than from PCPs.
Factor 5. Quality before cost: the variation in the extent 
to which PCPs perceived the balance between quality of 
care and cost was linked with how much PCPs themselves 
were directly affected by considerations of cost.
strengths and weaknesses of the study
There were participating centres in four countries from each 
of the Central, Eastern, Northern, Southern and Western 
European geographical areas, providing variation in geog-
raphy, health systems and levels of healthcare spending. It 
included the views of PCPs who are not usually involved in 
research. The questionnaire was carefully developed and 
piloted by GPs and other PCPs, and therefore grounded in 
their clinical experience. The sensitivity analysis suggested 
that the factor structure is robust and not driven by coun-
tries with larger numbers of respondents.
While low survey response rates are common in primary 
care35 and are known to vary between countries, the 
response rates in our study were comparable to those of 
a recent ICBP survey, in which response rates varied from 
5.5% to 45.6%.26 As the survey was anonymous, we have no 
data on non-responders. It is possible that the PCPs with the 
Table 5 Health system items and their factor analysis loadings The highest-scoring component for each item is italicised.
Health system item Component
Factor 1 1 2 3 4 5
  I am able to refer to a specialist that I know personally. 0.68 0.42 0.09 0.03 −0.14
  Here, specialists usually welcome referrals. 0.68 0.02 0.12 −0.04 −0.11
  I can easily telephone (or email) a specialist for informal discussion and advice. 0.68 −0.12 0.11 0.17 −0.12
  I am able to refer directly to a named specialist. 0.62 0.22 0.22 0.13 −0.26
  I usually have enough time in the consultation to think carefully about whether 
the patient needs a referral.
0.57 −0.02 −0.32 0.07 0.12
  My colleagues sometimes criticise me if I have referred a patient to them, but 
they think that I should have been able to manage the patient myself.
−0.51 0.25 0.14 0.12 0.31
Factor 2
  Seeing a specialist can be a problem for some of my patients because of the 
financial cost to them.
−0.08 0.59 −0.17 0.27 0.24
  We have access to a fast-track specialist appointment system for patients with 
suspected cancer.
0.05 −0.54 0.34 0.34 −0.03
  We have a budget or quota (maximum limit) for diagnostic tests. −0.27 0.54 −0.06 0.25 −0.26
  Referral costs are usually paid by insurance companies, not hospital or primary 
care budgets.
0.30 0.46 −0.05 −0.19 0.23
  Patients can self-refer to specialists, so GPs do not need to act as gatekeepers. 0.34 0.44 0.04 −0.30 0.11
  In my practice, patients often have to travel a long way to see a specialist. −0.26 0.38 −0.09 0.37 0.36
Factor 3
  I am usually very busy, so I sometimes refer to help reduce my workload. −0.32 0.19 0.60 −0.09 −0.01
  I am likely to refer if the patient says that she/he would like to be referred, even if 
there are no ‘red flags’.
−0.02 0.29 0.53 −0.34 0.16
  We are under media (newspaper, television) or public pressure to refer earlier. −0.20 0.08 0.51 −0.09 −0.16
  The local health system encourages us to refer any patients with possible cancer 
early, even if there is a low risk of cancer.
0.26 0.11 0.36 0.23 0.20
Factor 4
  Common presentations are covered by local or national guidelines that usually 
give advice on which patients to refer
0.05 −0.25 0.33 0.55 0.15
  In general, patients prefer a GP, rather than a specialist, to look after them. 0.25 0.19 −0.02 0.41 0.08
Factor 5
  Here, high-quality care for an individual patient is always more important than 
costs. 0.30 −0.26 0.01 0.05 0.57
  Referring or not referring does not affect me at all financially. 0.31 −0.29 0.08 −0.34 0.55
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most interest in this subject were the most likely to respond. 
However, while this selection bias may have affected the 
factor loadings, it is unlikely to have changed the factor 
structure itself.
While the demographic data that we collected included 
the gender of participants and the number of years that 
they had been in practice, we have found no equivalent 
data on national PCP populations that would allow us to 
assess how representative our samples were.
Most samples were taken from each local lead’s own 
locality, and these may not have been representative of their 
nations as a whole.36 While this makes it difficult to gener-
alise the findings to each country, the variation between 
countries is relevant and valid. The recruitment method 
used in this study resulted in variable response rates, 
leading to a risk of non-response bias and loss of power.35 
However, the goal of 50 survey participants per centre and 
>1000 respondents in total was achieved.
Participants’ responses may have been influenced by 
previous questions, and there may have been country-level 
differences in response styles, for instance, choosing or 
avoiding the ‘extreme’ options on the scale.37 As the trans-
lation also included a cultural adaptation we believe this 
bias was minimised, and the differences between countries 
cannot simply be explained by differences in response 
styles.
The five factors accounted for 47.4% of the variance in 
PCPs’ responses, and it is acceptable to consider a solution 
Figure 1 Comparison of national scores for factor 1: 
primary care practitioner’s ability to refer. A higher score 
indicated lower barriers to specialist referral.
Figure 2 Comparison of national scores for factor 2: degree 
of direct patient access to secondary care. A higher score 
was linked with the absence of a general practitioner gate-
keeping role, but higher financial and geographical barriers to 
healthcare for some patients.
Figure 3 Comparison of national scores for factor 3: 
pressure on primary care practitioners from outside. A higher 
score was linked with perceptions of higher pressure on the 
primary care practitioner. 
Figure 4 Comparison of national scores for factor 4: 
expectations of the primary care practitioner’s (PCPs') role. 
A higher score was associated with higher expectations of 
PCP-centred care, and the presence of guidelines to support 
PCP decision-making. 
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that accounts for 60% or less of the total variance as satis-
factory.38 Two of the factors only included two items each, 
which makes them vulnerable to missing responses and 
stochastic variation.
Comparison with other studies
To our knowledge, this is the first study that has been 
designed to identify the factors underlying PCPs’ referral 
decision-making, and provide international comparisons 
of the extent to which PCPs themselves perceive these as 
important. An ICBP narrative review compared the char-
acteristics of healthcare systems of six countries (Australia, 
Canada, Denmark, Norway, Sweden and the UK), aiming 
to identify characteristics that could possibly modify the 
diagnostic pathway.39 However, unlike our study, it only 
explored the systems of relatively wealthy countries, and 
it did not examine PCPs’ own perceptions of how their 
systems affected their decision-making. Our finding that 
PCPs in different European countries perceive different 
levels of access to investigations and specialist opinions 
may be relevant to the finding of varying referral delays in 
three European countries (Scotland, the Netherlands and 
Sweden).40
Possible implications for clinicians and policymakers
Five health system factors were able to explain nearly half 
of the variation in the PCPs’ responses to the items. This 
indicates that a relatively large part of the variation may be 
explained by differences between the health systems. Our 
study indicates the policy domains where countries might 
be able to modify their systems to better support their GPs 
and other PCPs in the timely referral and investigation of 
patients who could have cancer.
The most important of these factors were the ease of 
PCPs’ ability to refer, and the degree of direct patient access 
to secondary care. These factors are key in supporting 
earlier and expedited cancer diagnosis and may thus be 
linked with cancer outcomes. It therefore seems plausible 
that some countries could improve their cancer outcomes 
by providing better access to investigations and secondary 
care when cancer is suspected.
unanswered questions and future research
The five factors and their related scores should be 
compared with national cancer outcomes. These outcomes 
could include mortality, stage distribution and patient eval-
uations. An additional area of study could be to relate the 
factors and scores to national health system costs.
COnClusiOns
This research has developed a 20-item questionnaire 
with good content and construct validity, and has identi-
fied five factors that PCPs perceive to affect their referral 
decision-making in patients that could have cancer. These 
appear to vary depending on the different European 
models of primary care. This understanding of the inter-
action between health system variables and PCP deci-
sion-making can help in an exploration of the differences in 
national cancer diagnostic pathways and cancer outcomes, 
and could help to inform health service policy and research 
towards better cancer outcomes.
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